MetLife Investment Management’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

MetLife Investment Management’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-13,379	Closed	-$169K	–	2341
2020 Q4	$169K	Hold	13,379	–	–	﹤0.01%	2069
2020 Q3	$131K	Hold	13,379	–	–	﹤0.01%	2090
2020 Q2	$133K	Hold	13,379	–	–	﹤0.01%	2119
2020 Q1	$118K	Buy	+13,379	New	+$132K	﹤0.01%	1985
2019 Q4	–	Sell	-8,973	Closed	-$52.8K	–	2344
2019 Q3	$52.8K	Hold	8,973	–	–	﹤0.01%	2324
2019 Q2	$108K	Hold	8,973	–	–	﹤0.01%	2354
2019 Q1	$108K	Hold	8,973	–	–	﹤0.01%	2293
2018 Q4	$113K	Hold	8,973	–	–	﹤0.01%	2242
2018 Q3	$133K	Hold	8,973	–	–	﹤0.01%	2311
2018 Q2	$151K	Hold	8,973	–	–	﹤0.01%	2050
2018 Q1	$205K	Hold	8,973	–	–	﹤0.01%	1878
2017 Q4	$232K	Buy	+8,973	New	+$181K	﹤0.01%	1852

Other funds holding CNCE

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MetLife Investment Management's CNCE Position: Q1 2021 in Review

MetLife Investment Management sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2021, closing a stake of 13,379 shares — an estimated $169K sold.

MetLife Investment Management first reported a position in CNCE in Q4 2017 and held it in 12 quarters. The position peaked at $232K in Q4 2017. 91 funds tracked by Wall St. Rank hold CNCE as of Q1 2021.

MetLife Investment Management reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2021 after selling out during the quarter.
MetLife Investment Management sold 13,379 Concert Pharmaceuticals, Inc. shares in Q1 2021, an estimated $169K.
MetLife Investment Management first reported a position in Concert Pharmaceuticals, Inc. in Q4 2017 and held it in 12 quarters.
MetLife Investment Management's Concert Pharmaceuticals, Inc. position peaked at $232K in Q4 2017.
91 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2021.

Based on MetLife Investment Management's 13F filing for Q1 2021, filed 14 May 2021.